NCT04837859View on ClinicalTrials.gov

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG

Tislelizumab

age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients

Trial Locations (1)

Unknown

RECRUITING

1st Department of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER